dc.contributor.author | Gokturk, Suut | |
dc.contributor.author | Baran, Bulent | |
dc.contributor.author | Gulluoglu, Mine | |
dc.contributor.author | Ormeci, Asli Cifcibasi | |
dc.contributor.author | Evirgen, Sami | |
dc.contributor.author | Akyuz, Filiz | |
dc.contributor.author | Kaymakoglu, Sabahattin | |
dc.contributor.author | Soyer, Ozlem Mutluay | |
dc.contributor.author | Demir, Kadir | |
dc.contributor.author | Bozbey, Hamza Ugur | |
dc.contributor.author | Onel, Derya | |
dc.contributor.author | Karaca, Cetin | |
dc.contributor.author | Besisik, Fatih | |
dc.contributor.author | Badur, Selim | |
dc.date.accessioned | 2021-03-05T19:23:28Z | |
dc.date.available | 2021-03-05T19:23:28Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | Baran B., Soyer O. M. , Ormeci A. C. , Gokturk S., Evirgen S., Bozbey H. U. , Akyuz F., Karaca C., Demir K., Besisik F., et al., "Efficacy of Tenofovir in Patients with Lamivudine Failure Is Not Different from That in Nucleoside/Nucleotide Analogue-Naive Patients with Chronic Hepatitis B", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, cilt.57, sa.4, ss.1790-1796, 2013 | |
dc.identifier.issn | 0066-4804 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_cf0c9806-787c-4777-bffe-10e42d3c26da | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/136930 | |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84875189825&origin=inward | |
dc.identifier.uri | https://doi.org/10.1128/aac.02600-12 | |
dc.description.abstract | We evaluated the efficacy of tenofovir disoproxil fumarate (TDF) in patients with lamivudine failure (LAM-F) in comparison with that in nucleoside/nucleotide analogue (NA)-naive patients with chronic hepatitis B (CHB). The criteria for inclusion were being NA naive or having previous LAM-F and receiving TDF therapy for at least 6 months. Biochemical and virological tests were performed at the baseline, at 3-month intervals in the first year, and every 6 months thereafter. The primary outcome measure for efficacy was a complete virological response (CVR), defined as an HBV DNA level of <20 IU/ml. CVR rates were calculated by Kaplan-Meier analysis, and a multivariate Cox proportional-hazard model was generated in order to find predictive factors independently associated with the time to a CVR. We included 197 patients in the study (136 males; mean age, 43 +/- 12 years; 105 patients were NA naive). Sixty-five patients had hepatitis B e antigen (HBeAg)-positive CHB. The median duration of TDF treatment was 29 (range, 6 to 52) months. Seventy-one patients (77%) in the LAM-F group were treated with TDF add-on therapy. The CVR rates of the NA-naive and LAM-F groups were comparable in HBeAg-negative (94% versus 96% at month 36, P = 0.10) and HBeAg-positive patients (67% versus 83% at month 36, P = 0.48). According to the multivariate Cox regression model, only HBeAg positivity (hazard ratio [HR], 0.39; 95% confidence interval [CI], 0.26 to 0.59; P < 0.001) and a high baseline HBV DNA level (HR, 0.44; 95% CI, 0.29 to 0.67; P < 0.001) had a significant influence on the time to a CVR. The similar cumulative CVR rates during the follow-up show that TDF has comparable efficacy in lamivudine-experienced and NA-naive patients, and the presence of resistance mutations did not alter the response rates. | |
dc.language.iso | eng | |
dc.subject | Health Sciences | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Temel Bilimler | |
dc.subject | Pharmacology | |
dc.subject | General Pharmacology, Toxicology and Pharmaceutics | |
dc.subject | Pharmacology, Toxicology and Pharmaceutics (miscellaneous) | |
dc.subject | Pharmacology (medical) | |
dc.subject | Pharmacy | |
dc.subject | Drug Guides | |
dc.subject | Life Sciences | |
dc.subject | Mikrobiyoloji | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | FARMAKOLOJİ VE ECZACILIK | |
dc.subject | Farmakoloji ve Toksikoloji | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Eczacılık | |
dc.subject | Temel Eczacılık Bilimleri | |
dc.title | Efficacy of Tenofovir in Patients with Lamivudine Failure Is Not Different from That in Nucleoside/Nucleotide Analogue-Naive Patients with Chronic Hepatitis B | |
dc.type | Makale | |
dc.relation.journal | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | |
dc.contributor.department | İstanbul Üniversitesi , , | |
dc.identifier.volume | 57 | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 1790 | |
dc.identifier.endpage | 1796 | |
dc.contributor.firstauthorID | 5022 | |